| Literature DB >> 35771842 |
Nousheen Aslam1, Muhammad Harris Shoaib1, Rabia Bushra2, Saima Asif3, Yusra Shafique4.
Abstract
This study was conducted to determine the various socio-demographic, economic, and clinical variables (SDECVs) which influence the health-related quality of life (HRQoL) of hypertensive patients. Three hundred and fifty hypertensive patients participated in this study through a structured questionnaire and EQ 5D 5L. 211(60.28%) participants had stage 1, and 139 (39.7%) had stage 2 hypertension. No participants reported severe problems in any domain on EQ 5D 5L. Generalize Linear Model (GLM) was used to assess the association between HRQoL and SDECVs. The mean utility and VAS score was 0.64 (±0.15) and 63.17 (±11.01) respectively. The participants of the stage 1 hypertension group had a significantly better score on each domain of EQ 5D 5L as compared to stage 1 (0.027, 0.010, 0.00, 0.00, 0.048). No participant in either group reported extreme problems in any domain. Among socio-demographic factors, the males, non-smokers, income sharing, and healthy normal hypertensive patients had better HRQoL (0.009, 0.016, 0.019, and 0.003). A lower cost of treatment was also associated with better HRQoL (0.017). Among clinical variables, stage 1 hypertension had better HRQoL than stage 2(0.035). The number of prescribed antihypertensive drugs had no effect on the quality of life (0.253), however, the non-pharmacologic interventions such as reduction in salt and oil consumption (0.035), reduction in beverages consumption (0.0014) and increased water intake (0.010) had resulted in better QoL. The patients who reported dizziness had poor HRQoL while patients who had cardiac problems and diabetes reported a significantly lower EQ-VAS score. The effect of gender on the HRQoL of hypertensive patients who had comorbid conditions was significant in the case of renal, respiratory, visual problems, and dizziness where females had a lesser utility score than males. The study reports on significant determinants which should be taken into account in an attempt to improve the health-related quality of life of hypertensive patients.Entities:
Mesh:
Year: 2022 PMID: 35771842 PMCID: PMC9246217 DOI: 10.1371/journal.pone.0270587
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.752
Socio-demographic characteristics.
| Codes* | Characteristics | Stage 1(N = 211, 60.28%) | Stage 2 (N = 139, 39.7%) |
|---|---|---|---|
|
| 53.39 ±10.32 | 54.69 ± 11.38 | |
|
|
| 46 (21.8%) | 21(15.6%) |
|
|
| 112 (53.1%) | 75 (38.8%) |
|
|
| 46 (21.8%) | 35 (15.7%) |
|
|
| 7 (3.31%) | 68 (2.4%) |
|
| |||
|
|
| 97 (45.97%) | 66 (47.48%) |
|
|
| 114 (54.02%) | 73 (52.5%) |
|
|
| 131.13(±9.59) | 165.79 (±16.65) |
|
|
| 98.85 (±16.46) | 102.23(±14.9) |
|
| |||
|
| 129 (61.1%) | 24 (17.2%) | |
|
| 64 (30.3%) | 83 (59.7%) | |
|
|
| 18 (8.5%) | 32 (23.07%) |
|
| |||
|
|
| 201(95.2%) | 130 (93.5%) |
|
|
| 4 (1.89%) | 3 (2.15%) |
|
|
| 6 (2.84%) | 3 (2.15%) |
|
| |||
|
|
| 99 (46.91%) | 50 (35.97%) |
|
|
| 49 (23.2%) | 28 (20.14%) |
|
|
| 40 (18.95%) | 37 (26.6%) |
|
|
| 23 (10.9%) | 24 (17.2%) |
|
| |||
|
|
| 144 (68.24%) | 100 (71.9%) |
| _Household Head | 100 (69.4%) | 78 (78%) | |
| _Income Sharing | 44 (30.5%) | 22 (15.82%) | |
|
|
| 67 (31.75%) | 39 (28.05%) |
|
| 7 ±2.2 | 6.8 ±2 | |
|
|
| 4 (21.32%) | 35(25.17%) |
|
|
| 154 (72.98%) | 100 (71.94%) |
|
|
| 12 (5.68%) | 4 (2.87%) |
|
| |||
|
|
| 63 (29.85%) | 46 (33%) |
|
|
| 86 (40.75%) | 47 (33.81%) |
|
|
| 62 (29.38%) | 46 (33%) |
|
| |||
|
|
| 0 | 0 |
|
|
| 211(100%) | 139 (100%) |
|
| |||
|
|
| 15 (7.10%) | 7 (5.03%) |
|
|
| 174(82.46%) | 94(67.62%) |
Percent response to each level of five dimensions on EQ-5D 5L.
| Dimensions of EQ-5D | Level | Level Description | % Response | ||
|---|---|---|---|---|---|
| Stage 1 N (%) | Stage 2 N (%) | Difference | |||
|
|
|
| 111 (52.6) | 59(42.44) | |
|
|
| 7(3.31) | 69(49.64) | 0.027 | |
|
|
| 84(39.81) | - | ||
|
|
| 9(4.26) | 11(7.9) | ||
|
|
| - | - | ||
|
|
|
| 107(50.7) | 53(38.12) | |
|
|
| 11(5.21) | 77(55.39) | 0.010 | |
|
|
| 90(42.65) | 5(3.59) | ||
|
|
| 3(1.42) | 4(2.87) | ||
|
|
| - | - | ||
|
|
|
| 72(34.12) | 48(34.5) | |
|
|
| 7(3.31) | 64(46) | 0.00 | |
|
|
| 127(60.18) | 15(10.79) | ||
|
|
| 5(2.36) | 12(8.63) | ||
|
|
| - | - | ||
|
|
|
| 64(30.33) | 33(23.7) | |
|
|
| 9(4.26) | 64(46) | 0.00 | |
|
|
| 118(55.9) | 15(10.79) | ||
|
|
| 20(9.4) | 12(8.63) | ||
|
|
| - | - | ||
|
|
|
| 92(43.6) | 55(39.56) | |
|
|
| 9(4.26) | 55(29.56) | 0.048 | |
|
|
| 94(44.54) | 15(10.79) | ||
|
|
| 16(7.58) | 14(10) | ||
|
|
|
|
| ||
p-value is significant at <0.05.
Generalize linear model (GLM) to predict the effect of SDEC variables on EQ 5D 5L domains.
| Mobility | Self-care | Usual activities | Pain/ Discomfort | Anxiety/ Depression | |
|---|---|---|---|---|---|
|
| |||||
|
| 0.940 | 0.361 | 0.524 |
|
|
|
| 0.710 | 0.109 |
| 0.082 | 0.549 |
|
| 0.252 |
| 0.862 | 0.397 | 0.904 |
|
| 0.553 | 0.518 | 0.353 |
| 0.359 |
|
| 0.054 | 0.134 | 0.052 | 0.146 | 0.266 |
|
|
| 0.451 | 0.085 |
|
|
|
| |||||
|
|
|
|
|
|
|
|
| 0.077 |
| 0.947 | 0.943 | 0.644 |
|
| 0.575 |
| 0.268 |
| 0.306 |
|
| 0.995 | 0.850 |
| 0.805 | 0.573 |
|
| 0.272 | 0.256 |
| 0.288 | 0.846 |
|
| 0.560 |
| 0.861 |
|
|
|
|
|
|
|
| 0.074 |
The table represents only those SDECV who have significant association with at least one of the five domains of EQ 5D 5L.
*significant values
Effect of socio-demographic, economic and clinical variables on health related quality of life.
|
| ||||||
|
|
| |||||
|
|
|
|
|
| ||
|
| Male | 163 | 0.659(±0.13) |
| 62.84(±11.7) |
|
| Female | 187 | 0.616(±0.18) | 60.5(±11.4) | |||
|
| Yes | 22 | 0.6003(0.14) | 0.113 | 57.72(11.1) |
|
| No | 268 | 0.654(0.15) | 63.56(10.01) | |||
|
| 2–5 | 81 | .6592(.14833 | 0.538 | 63.5556(12.4) | 0.622 |
| 6–10 | 255 | .6471(.15506 | 63.2157(10.7) | |||
| 11–20 | 14 | .6191(.09335 | 60.(8.98) | |||
|
| household heads | 178 | 0.63 (0.16) |
| 62(10.9) |
|
| income sharing | 66 | 0.69 (0.12) | 65.3(10.6) | |||
| Not earning/dependent | 106 | 0.65(0.14) | 63.7(11.4) | |||
|
| Healthy Normal | 285 | 0.66(0.14) |
| 63.16 (11.1) | 0.503 |
| Overweight | 58 | 0.618(0.19) | 63.6(10.9) | |||
| Obese | 6 | 0.64(0.139) | 57.5(10.8) | |||
|
| 10–50,000 | 263 | 0.62(0.10) |
| 63.72 (6.49) | 0.371 |
| 51–100,000 | 69 | 0.631 (0.17) | 64.27(4.61) | |||
| Above 100,000 | 18 | 0.64(0.13) | 64.95(3.0) | |||
|
| 100,000–200,000 | 166 | 0.66(0.08) |
| 61.5(10.2) | 0.750 |
|
| ||||||
|
| Stage 1 | 211 | 0.649 (±0.1) |
| 64 (±10.6) |
|
| Stage 2 | 139 | 0.647 (±0.16) | 61(±11.6) | |||
| Above 200,000 | 184 | 0.648 (0.15) | 63.5(11.1) | |||
|
| Yes | 278 | 0.659(±0.13) |
| 62.84(±11.7) |
|
| No | 72 | 0.61(0.17) | 60.3(10.35) | |||
|
|
| |||||
|
|
|
|
|
| ||
|
| Yes | 281 | 0.64(0.15) |
| 64(11.1) | 0.26 |
| No | 68 | 0.67(0.12) | 658(11)0.260 | |||
|
| Yes | 295 | 0.65(0.15) |
| 63.8(11.2) | 0.686 |
| No | 55 | 0.64(0.12) | 59.6(9.66) | |||
|
| Yes | 222 | 0.65(0.14) | 0.71 | 62.9(11.1) | 0.9 |
| No | 127 | 0.648(0.15) | 63.4(11.1) | |||
|
| 1 | 67 | 0.65(0.15) | 0.253 | 63.95(10.4) | 0.056 |
| 2 | 199 | 0.656(0.146) | 63.99(11.2) | |||
| 3 | 83 | 0.648(0.151) | 60.84(11.7) | |||
|
| 1 | 16 | 0.6(0.21) |
| 68.13(11.6) | 0.067 |
| 2 | 40 | 0.72(0.11) | 65.2(11) | |||
| 3 | 293 | 0.64(0.15) | 62.6(11) | |||
|
| Yes | 292 | 0.655(0.14) | 0.182 | 62.8(11.1) | 0.124 |
| No | 57 | 0.62(0.18) | 64.9(10.75) | |||
|
| Yes | 294 | 0.652(0.14) | 0.150 | 62.7(11.1) | 0.339 |
| No | 55 | 0.633(0.175) | 65(10.8) | |||
|
| Yes | 147 | 0.64(0.147) | 0.773 | 63.5(10.4) | 0.608 |
| No | 203 | 0.65 (0.145) | 62.9(11.6) | |||
|
| Yes | 115 | 0.64 (0.165) | 0.227 | 61.1(11.38) |
|
| No | 235 | 0.66 (0.14) | 64.18(10.8) | |||
|
| Yes | 250 | 0.61(0.15) |
| 63.0 | 0.722 |
| No | 100 | 0.71(0.07) | 63.5 | |||
|
| Yes | 187 | 0.64(0.159) | 0.968 | 62(11.3) |
|
| No | 162 | 0.648(0.142) | 64.4(10.6) | |||
*Independent Sample t-test;
**ANOVA, p-value is significant at <0.05
Fig 1(a) Utility Scores of hypertensive patients (N = 350) (b) EQ Visual Analogue Scale (EQ VAS) of hypertensive patients (N = 350).
Effect of gender on HRQoL of hypertensive patients with different Co-morbid conditions.
| Effect of Gender on HRQoL of hypertensive patients with different Co-morbid conditions | ||||||
|---|---|---|---|---|---|---|
| Comorbid Condition | Gender | N | EQ 5D Index value | EQ VAS Score | ||
| (Mean ± SD) | (Mean ± SD) | |||||
|
| Male | 123 | 0.68(0.13) |
| 64.5 (11.0) |
|
| Females | 169 | 0.63(0.162) | 61(11.0) | |||
|
| Male | 125 | 0.674(0.12) |
| 64 (11.01) |
|
| Female | 169 | 0.625(0.166) | 61 (11.01) | |||
|
| Male | 74 | 0.67(0.133) |
| 63.45(10.1) | 0.947 |
| Female | 73 | 0.622(0.15) | 63.58(10.74) | |||
|
| Male | 96 | 0.70(0.092) |
| 60.52(10.65) | 0.807 |
| Female | 19 | 0.623(0.174) | 61.19(11.57) | |||
|
| Male | 128 | 0.625 (0.13) | 0.149 | 64.4 (10.64) |
|
| Female | 122 | 0.60(0.17) | 61.7 (10.80) | |||
|
| Male | 49 | 0.66(0.13) | 0.709 | 63.5(11.27) | 0.766 |
| Female | 138 | 0.66(0.144) | 62.95(10.74) | |||
p-value is significant at <0.05